RudolfR, KhanMM, LustrinoD, LabeitS, KettelhutIC, NavegantesLC: Alterations of cAMP-dependent signaling in dystrophic skeletal muscle. Front Physiol, 2013; 4:290.
2.
TizianoFD, LomastroR, PintoAM, et al.: Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet, 2010; 47:856–858.
3.
PaneM, StaccioliS, MessinaS, et al.: Daily salbutamol in young patients with SMA type II. Neuromuscul Disord, 2008; 18:536–540.
4.
AraiK, WoodJP, OsborncNN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res, 2003; 985:176–186.
5.
RhoDS: Acute angle-closure glaucoma after albuterol nebulizer treatment. Am J Ophthalmol, 2000; 130:123–124.
6.
BrombergBB: Autonomic control of lacrimal protein secretion. Invest Ophthalmol Vis Sci, 1981; 20:110–116.
7.
MenerayMA, FieldsTY: Adrenergic stimulation of lacrimal protein secretion is mediated by G(q/11)alpha and G(s)alpha. Curr Eye Res, 2000; 21:602–607.
8.
PatteC, DeruelleP: A critical appraisal of the misoprostol removable, controlled-release vaginal delivery system of labor induction. Int J Womens Health, 2015; 7:889–899.
9.
SmithJM, GubinR, HolstonMM, FullertonJ, PrataN: Misoprostol for postpartum hemorrhage prevention at home birth: an integrative review of global implementation experience to date. BMC Pregnancy Childbirth, 2013; 13:44.
10.
RockallTA: Misoprostol for NSAID-induced small bowel erosions and ulcers. Lancet Gastroenterol Hepatol, 2018; 3:447–448.
11.
AronoffDM, HaoY, ChungJ, et al.: Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol, 2008; 180:8222–8230.
12.
RatnaikeRN, JonesTE: Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging, 1998; 13:245–253.
13.
LiF, HeB, MaX, et al.: Prostaglandin E1 and its analog misoprostol inhibit human CML stem cell self-renewal via EP4 receptor activation and repression of AP-1. Cell Stem Cell, 2017; 21:359–373.e5.
14.
RajamuthiahR, FuchsBB, ConeryAL, et al.: Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS One, 2015; 10:e0124595.
15.
WuX, CherianPT, LeeRE, HurdleJG: The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother, 2013; 68:806–815.
AlbertsDS, DorrRT, EinspahrJG, et al.: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev, 2000; 9:1281–1286.
19.
McCormackSA, TagueLL, GragoeEJJr, JohnsonLR: Regulation of ornithine decarboxylase activity in LoVo cells. Am J Physiol, 1990; 258(6 Pt 1):G934–G941.
20.
GrahamDP, NielsenDA, KostenTR, et al.: Examining the utility of using genotype and functional biology in a clinical pharmacology trial: pilot testing dopamine β-hydroxylase, norepinephrine, and post-traumatic stress disorder. Psychiatr Genet, 2014; 24:181–182.
21.
SchroederJP, EppsSA, GriceTW, WeinshenkerD: The selective dopamine β-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology, 2013; 38:1032–1038.
22.
BonifácioMJ, SousaF, NevesM, et al.: Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat. Eur J Pharmacol, 2015; 751:50–58.
23.
MeltzerHY, ZhangY, StockmeierCA: Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol, 1992; 216:67–71.
BickerJ, AlvesG, FortunaA, Soares-da-SilvaP, FalcãoA: In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. Eur J Pharm Sci, 2018; 117:35–40.
26.
SonierB, ArseneaultM, LavigneC, OuelletteRJ, VaillancourtC: The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun, 2006; 343:1053–1059.
KelleyWN, WyngaardenJB: Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells. J Clin Invest, 1970; 49:602–609.
29.
ToghaM, AkhondzadehS, MotamediM, AhmadiB, RazeghiS: Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch Med Res, 2007; 38:313–316.
30.
DeMarcoP, ZagnoniP: Allopurinol and severe epilepsy. Neurology, 1986; 36:1538–1539.
31.
GieraS, DengY, LuoR, et al.: The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development. Nat Commun, 2015; 6:6121.
32.
AckermanSD, GarciaC, PiaoX, GutmannDH, MonkKR: The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Gα12/13 and RhoA. Nat Commun, 2015; 6:6122.
33.
BeboBFJr, DehghaniB, FosterS, KurniawanA, LopezFJ, ShermanLS: Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia, 2009; 57:777–790.
34.
EllosoMM, PhielK, HendersonRA, HarrisHA, AdelmanSJ: Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol, 2005; 185:243–252.
35.
AmabebeE, AnumbaDOC: The vaginal microenvironment: the physiologic role of lactobacilli. Front Med (Lausanne), 2018; 5:181.
36.
MachadoA, CercaN: Influence of biofilm formation by Gardnerella vaginalis and other anaerobes on bacterial vaginosis. J Infect Dis, 2015; 212:1856–1861.
37.
ZilnyteM, Venclovas Č, ZvirblieneA, PleckaityteM: The cytolytic activity of vaginolysin strictly depends on cholesterol and is potentiated by human CD59. Toxins (Basel), 2015; 7:110–128.
38.
AbdelmaksoudAA, GirerdPH, GarciaEM, et al.: Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity. PLoS One, 2017; 12:e0183765.
39.
JobER, BottazziB, GilbertsonB, et al.: Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses. PLoS One, 2013; 8:e59623.
40.
MurrayLA, ChenQ, KramerMS, et al.: TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol, 2011; 43:154–162.
41.
KarhadkarTR, PillingD, CoxN, GomerRH: Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model. Sci Rep, 2017; 7:15069.
42.
ReissAB, ShahN, MuhieddineD, et al.: PCSK9 in cholesterol metabolism: from bench to bedside. Clin Sci (Lond), 2018; 132:1135–1153.
43.
GustafsenC, OlsenD, VilstrupJ, et al.: Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun, 2017; 8:503.
44.
SeidahNG, MayerG, ZaidA, et al.: The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol, 2008; 40:1111–1125.
